HitGen Inc
SSE:688222

Watchlist Manager
HitGen Inc Logo
HitGen Inc
SSE:688222
Watchlist
Price: 12.07 CNY -7.08% Market Closed
Market Cap: 4.8B CNY
Have any thoughts about
HitGen Inc?
Write Note

HitGen Inc
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

HitGen Inc
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
HitGen Inc
SSE:688222
Additional Paid In Capital
ÂĄ759.1m
CAGR 3-Years
0%
CAGR 5-Years
19%
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Additional Paid In Capital
ÂĄ25.5B
CAGR 3-Years
1%
CAGR 5-Years
17%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Additional Paid In Capital
ÂĄ5.2B
CAGR 3-Years
-5%
CAGR 5-Years
28%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Additional Paid In Capital
ÂĄ23B
CAGR 3-Years
-5%
CAGR 5-Years
28%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Additional Paid In Capital
ÂĄ10.8B
CAGR 3-Years
-3%
CAGR 5-Years
44%
CAGR 10-Years
41%
W
WuXi XDC Cayman Inc
HKEX:2268
Additional Paid In Capital
ÂĄ4.9B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

HitGen Inc
Glance View

Market Cap
4.8B CNY
Industry
Life Sciences Tools & Services

HitGen, Inc. engages in the provision deoxyribonucleic acid encoded compound library (DEL) for research and development of seed and lead compounds. The company is headquartered in Chengdu, Sichuan and currently employs 508 full-time employees. The company went IPO on 2020-04-16. The firm focuses on the research and creation of deoxyribonucleic acid encoded compound library (DEL) technology, research and development of hit compounds and lead compounds. The firm mainly provides DEL screening services, DEL library customization services, chemical synthesis services and transfer of new drug research and development projects. The firm conducts its businesses within the domestic market and to overseas markets.

Intrinsic Value
7.23 CNY
Overvaluation 40%
Intrinsic Value
Price

See Also

What is HitGen Inc's Additional Paid In Capital?
Additional Paid In Capital
759.1m CNY

Based on the financial report for Dec 31, 2023, HitGen Inc's Additional Paid In Capital amounts to 759.1m CNY.

What is HitGen Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
19%

Over the last year, the Additional Paid In Capital growth was 0%.

Back to Top